A new analysis of clinical trial data reveals that people taking the oral form of Wegovy achieved significant weight loss and meaningful improvements in everyday physical activities like bending and standing. Nearly one in three adults who responded early to the medication lost an average of 21.6% of their body weight by the end of the trial, while those who responded more slowly still achieved clinically meaningful weight loss of 11.5%.

What Makes Early Response to Weight Loss Treatment Important?

Researchers presented new findings from the OASIS 4 clinical trial at the European Congress on Obesity in May 2026, focusing on how quickly people respond to oral semaglutide, the active ingredient in Wegovy pill. The trial included adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. Among participants, 28.8% were classified as "early responders," meaning they lost at least 10% of their body weight within the first 16 weeks of treatment.

Understanding early response patterns matters because it helps both patients and doctors set realistic expectations and adjust treatment plans accordingly. Early responders who achieved 13.2% weight loss by week 16 went on to reach 21.6% weight loss by the end of the 64-week trial, while non-early responders still achieved meaningful results of 11.5% weight loss.

"It is important for patients and healthcare professionals to understand that there are differences in the early rapidity of weight loss following initiation of treatment with oral semaglutide 25 mg, and how this can signal the longer-term degree of weight loss that may be achieved," said Prof. W. Timothy Garvey, Department of Nutrition Sciences, University of Alabama at Birmingham.

Prof. W. Timothy Garvey, Department of Nutrition Sciences, University of Alabama at Birmingham

How Does Wegovy Pill Improve Physical Function Beyond Weight Loss?

Beyond the numbers on the scale, the trial revealed something many people find equally important: the ability to move more freely. Among participants who had poor physical function at the start of the trial, 77.3% of those taking Wegovy pill achieved clinically meaningful improvements in their ability to perform everyday activities, compared to just 42.9% in the placebo group. These improvements included better range of motion, increased stamina, and the ability to perform tasks like bending over and standing comfortably for extended periods.

This finding is significant because weight loss alone doesn't always translate directly to improved mobility. The medication appears to offer benefits that go beyond simply reducing body weight, potentially through effects on muscle function and overall physical capacity. People who experienced these mobility improvements also achieved similar weight loss results to the overall group taking Wegovy pill.

"The evidence base supporting the benefits of the Wegovy pill continues to grow. In addition to offering unmatched weight-loss efficacy in an oral obesity treatment, the data now underscores the meaningful improvements people can see in their day-to-day lives. Things many may take for granted, like the ability to stand for a length of time or simply bending down, can all be impacted by excess weight," stated Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.

Martin Holst Lange, Chief Scientific Officer and Executive Vice President, Research and Development at Novo Nordisk

How Does Oral Semaglutide Compare to Other Weight Loss Medications?

The trial data also included comparisons with another weight loss medication called orforglipron. The analysis showed that Wegovy pill delivered significantly greater weight loss than orforglipron 36 mg. More notably, people taking orforglipron were approximately 14 times more likely to stop taking the medication due to gastrointestinal side effects like nausea and vomiting. In a separate patient preference study, 84% of survey respondents favored a treatment profile similar to Wegovy pill over orforglipron.

The most common side effects reported with Wegovy pill were gastrointestinal in nature, but the vast majority were mild to moderate and diminished over time as the body adjusted to the medication. This tolerability profile is consistent with other medications in the GLP-1 receptor agonist class, which work by mimicking a hormone that helps regulate appetite and blood sugar.

Key Takeaways About Oral Semaglutide for Weight Management

• Early Response Matters: Nearly 29% of people taking oral Wegovy achieved early weight loss of at least 10% within 16 weeks, which predicted stronger long-term results of 21.6% weight loss by the end of treatment.
• Mobility Improvements: Among people with poor physical function, 77.3% experienced meaningful improvements in their ability to perform everyday activities like bending and standing, compared to 42.9% in the placebo group.
• Tolerability Profile: Gastrointestinal side effects were the most common, but they were typically mild to moderate and decreased over time, with fewer people stopping treatment due to side effects compared to other weight loss medications.
• Consistent Results Across Groups: Even people who did not respond early to treatment still achieved clinically meaningful weight loss of 11.5% by the end of the trial, demonstrating that the medication works for a broad range of patients.

The OASIS 4 trial included adults with obesity or overweight status who did not have type 2 diabetes. Participants were randomly assigned to receive either the Wegovy pill at 25 mg once daily or a placebo for 64 weeks. The trial's primary results showed an average weight loss of 17% for people taking Wegovy pill compared to 2.7% in the placebo group.

These findings add to a growing body of evidence about how oral semaglutide works in real-world settings. Semaglutide has accumulated nearly 49 million patient-years of exposure across various clinical trials and real-world studies, providing substantial safety data. The medication is approved by the FDA as both a once-daily pill and a once-weekly injection, with the pill formulation currently pending approval from the European Medicines Agency.